Allena Pharmaceuticals, Inc. (ALNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allena Pharmaceuticals, Inc. (ALNA) trades at $0.075 with AI Score 44/100 (Grade C). Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ALNA: ALNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALNA: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Allena Pharmaceuticals, Inc. (ALNA) Healthcare & Pipeline Overview
Allena Pharmaceuticals, Inc. is a biotechnology firm specializing in oral enzyme therapeutics for rare metabolic and kidney disorders, with ALLN-346 as its primary focus. The company operates within the competitive biotechnology sector, addressing unmet needs in chronic kidney disease and related conditions.
What Is the Investment Thesis for ALNA?
Allena Pharmaceuticals, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, ALLN-346, targeting hyperuricemia and gout in advanced chronic kidney disease patients. The potential for ALLN-346 to address a significant unmet need in this patient population is a key value driver. The company's success hinges on positive clinical trial outcomes and subsequent regulatory approval. Key risks include clinical trial failures, regulatory hurdles, and competition from existing and emerging therapies. With a P/E ratio of -0.07 and a beta of 1.15, the company reflects the inherent volatility and speculative nature of biotechnology investments. The absence of a dividend underscores the company's focus on reinvesting earnings into research and development.
Based on FMP financials and quantitative analysis
ALNA Key Highlights
- Lead product candidate ALLN-346 targets hyperuricemia and gout in advanced chronic kidney disease patients.
- Focus on oral enzyme therapeutics offers a potentially convenient treatment option.
- Strategic focus on rare and severe diseases allows for targeted patient populations and potential market exclusivity.
- Incorporated in 2011, indicating a relatively young company in the biotechnology space.
- Headquartered in Newton, Massachusetts, a hub for biotechnology and pharmaceutical companies.
Who Are ALNA's Competitors?
ALNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APGN Apexigen, Inc. | $0.39 | +8.48% | $9.57M | 44 |
| CHRO Channel Therapeutics Corporation | $1.35 | +7.14% | $8.90M | 44 |
| CRVO CervoMed Inc. | $2.89 | +3.58% | $26.8M | — |
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| EPIX ESSA Pharma Inc. | $0.20 | -1.85% | $9.52M | — |
| VRTX Vertex Pharmaceuticals Incorporated | $481.72 | +0.25% | $122B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $675.02 | +0.43% | $69.5B | 92 |
| ALNY Alnylam Pharmaceuticals, Inc. | $271.37 | -0.48% | $36.2B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALNA's Key Strengths?
- Proprietary enzyme technology platform
- Lead product candidate targeting a specific unmet need
- Experienced management team
- Focus on rare and severe diseases
What Are ALNA's Weaknesses?
- Limited financial resources
- Dependence on a single product candidate
- Small number of employees
- Lack of commercial infrastructure
What Could Drive ALNA Stock Higher?
- Clinical trial results for ALLN-346.
- Potential regulatory approval of ALLN-346.
- Strategic partnerships and collaborations.
- Expansion into new therapeutic areas.
What Are the Key Risks for ALNA?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from existing therapies.
- Limited financial resources.
- Dependence on a single product candidate.
What Are the Growth Opportunities for ALNA?
- Expansion into New Therapeutic Areas: Allena Pharmaceuticals, Inc. can leverage its expertise in enzyme therapeutics to expand into new therapeutic areas beyond hyperuricemia and gout. This could involve developing novel enzyme-based therapies for other metabolic or kidney disorders with unmet medical needs. Timeline: 3-5 years.
- Geographic Expansion: Allena Pharmaceuticals, Inc. can expand its geographic reach beyond the United States to target international markets with significant patient populations suffering from hyperuricemia and gout. This could involve establishing partnerships with international distributors or pursuing regulatory approvals in key markets such as Europe and Asia. The global market for gout treatment is expected to grow substantially, driven by increasing prevalence and aging populations. Timeline: 2-4 years.
- Strategic Partnerships and Collaborations: Allena Pharmaceuticals, Inc. can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. This could involve licensing agreements, co-development partnerships, or joint ventures. Collaborations can provide access to additional resources, expertise, and market access. Timeline: Ongoing.
- Development of Next-Generation Enzyme Therapeutics: Allena Pharmaceuticals, Inc. can invest in the development of next-generation enzyme therapeutics with improved efficacy, safety, and delivery methods. This could involve engineering novel enzymes with enhanced catalytic activity or developing innovative oral delivery systems to improve bioavailability. The market for advanced drug delivery technologies is rapidly growing, driven by the need for more effective and convenient therapies. Timeline: 5+ years.
- Acquisition of Complementary Technologies or Companies: Allena Pharmaceuticals, Inc. can pursue strategic acquisitions of complementary technologies or companies to expand its product pipeline and capabilities. This could involve acquiring companies with expertise in enzyme engineering, drug delivery, or related therapeutic areas. Acquisitions can provide access to new technologies, intellectual property, and talent. Timeline: Opportunistic.
What Opportunities Does ALNA Have?
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Geographic expansion
- Favorable regulatory environment for orphan drugs
What Threats Does ALNA Face?
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent expiration
What Are ALNA's Competitive Advantages?
- Proprietary enzyme technology
- Patent protection for ALLN-346
- Focus on rare and severe diseases
- Specialized expertise in enzyme therapeutics
What Does ALNA Do?
Allena Pharmaceuticals, Inc., founded in 2011 and headquartered in Newton, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing oral enzyme therapeutics. The company focuses on addressing unmet needs in patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-346, is a novel, orally administered enzyme designed to degrade urate in the gastrointestinal tract. This therapeutic approach aims to reduce the burden of hyperuricemia and gout, particularly in individuals with advanced chronic kidney disease (CKD). The company's research and development efforts are centered on enzyme-based therapies that can be administered orally, offering a convenient and potentially more effective treatment option for patients with these debilitating conditions. Allena's strategic focus on rare and severe diseases allows it to target specific patient populations with significant unmet medical needs, potentially leading to accelerated regulatory pathways and market exclusivity. The company's operations are currently based in the United States, with a focus on clinical development and eventual commercialization of its lead product candidate.
What Products and Services Does ALNA Offer?
- Discovers oral enzyme therapeutics
- Develops oral enzyme therapeutics
- Commercializes oral enzyme therapeutics
- Treats patients with rare metabolic disorders
- Treats patients with severe metabolic disorders
- Treats patients with rare kidney disorders
- Treats patients with severe kidney disorders
How Does ALNA Make Money?
- Develops and patents novel enzyme therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved products through sales and marketing efforts.
What Industry Does ALNA Operate In?
Allena Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The company's focus on rare and severe metabolic and kidney disorders positions it within a niche market with potentially less competition but also smaller patient populations. The biotechnology industry is driven by advancements in genomics, proteomics, and other areas of biological science, leading to the development of novel therapies for previously untreatable diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in various therapeutic areas.
Who Are ALNA's Key Customers?
- Patients with hyperuricemia and gout
- Patients with advanced chronic kidney disease
- Healthcare providers treating these patients
- Pharmacies dispensing the medication
Company Profile
Allena Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. The company is led by CEO Louis Brenner. ALNA has traded publicly since 2017.
ALNA Valuation & Market Position
Relative to its peer group, ALNA's quantitative score of 44/100 is roughly in line with the peer average of 50/100.
Key Financial Metrics
Return on assets is -96.0%, showing how much profit it generates from its asset base. A current ratio of 2.11 indicates the company holds enough short-term assets to cover its near-term obligations.
ALNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary enzyme technology platform
- Lead product candidate targeting a specific unmet need
- Experienced management team
- Focus on rare and severe diseases
Bear Case
- Limited financial resources
- Dependence on a single product candidate
- Small number of employees
- Lack of commercial infrastructure
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ALNA Latest News
No recent news available for ALNA.
ALNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALNA.
Price Targets
Wall Street price target analysis for ALNA.
ALNA MoonshotScore
What does this score mean?
The MoonshotScore rates ALNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Louis Brenner
CEO
Louis Brenner serves as the Chief Executive Officer of Allena Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. Prior to joining Allena, he held leadership positions at various biotechnology and pharmaceutical companies, where he was responsible for driving growth and innovation. He has a strong track record of building and managing successful teams, as well as executing strategic transactions.
Track Record: Under Louis Brenner's leadership, Allena Pharmaceuticals, Inc. has focused on advancing the clinical development of ALLN-346 and exploring strategic opportunities to expand its pipeline. Key milestones include initiating and completing clinical trials for ALLN-346 and securing funding to support the company's research and development efforts. He is managing 12 employees.
Common Questions About ALNA (Healthcare)
What does the AI Score mean for ALNA?
ALNA holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Their lead product candidate …
What does Allena Pharmaceuticals, Inc. do?
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics for patients with rare and severe metabolic and kidney disorders. Their lead product candidate, ALLN-346, is designed to treat hyperuricemia and gout in patients with advanced chronic kidney disease by degrading urate in the gastrointestinal tract. The company aims to provide convenient and effective treatment options for these debilitating conditions, addressing significant unmet medical needs.
What are the main risks for ALNA?
Allena Pharmaceuticals, Inc. faces several risks inherent to the biotechnology industry. These include the potential for clinical trial failures, regulatory hurdles in obtaining approval for ALLN-346, and competition from existing and emerging therapies. The company's limited financial resources and dependence on a single product candidate also pose significant risks. Patent expiration and the emergence of biosimilars could also impact future revenue streams.
What are the key growth opportunities for ALNA in healthcare?
Allena Pharmaceuticals, Inc. can explore expansion into new therapeutic areas, leveraging its expertise in enzyme therapeutics to address other metabolic and kidney disorders. Geographic expansion into international markets with significant patient populations also presents a growth opportunity. Strategic partnerships and collaborations with larger pharmaceutical companies can provide access to additional resources and expertise. The development of next-generation enzyme therapeutics with improved efficacy and delivery methods is another avenue for growth.
How does Allena Pharmaceuticals, Inc. manage patent expiration risks?
As ALLN-346 progresses through clinical trials and towards potential commercialization, Allena Pharmaceuticals, Inc. will need to proactively manage patent expiration risks. This involves continually innovating and developing new enzyme therapeutics or formulations to extend patent protection. The company can also pursue strategic partnerships and licensing agreements to diversify its product pipeline and reduce reliance on a single product.
What are the key factors to evaluate for ALNA?
Allena Pharmaceuticals, Inc. (ALNA) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ALNA data refresh on this page?
ALNA's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALNA's recent stock price performance?
Allena Pharmaceuticals, Inc. (ALNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary enzyme technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALNA overvalued or undervalued right now?
Allena Pharmaceuticals, Inc. (ALNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- AI analysis is pending, which may provide further insights.